BI & PXS Nash drug still has the potential to be the "Best in Class" Nash drug and this would be significant . Most advanced drug in NASH area is now Intercept´s (ICPT) Ocaliva but the drug has horrible side effects and weak efficacy another potential competitor is Gilead but their drug failed in late stage trials .There are other 2 companies (Genfit & Madrigal) who will report Phase 3 data in short term but i think these drugs will fail too .
Intercept, Intercepted Before The NASH Goal Line
https://seekingalpha.com/article/4276067-intercept-intercepted-nash-goal-line
NASH Phase 2 results imminent --A $20+ BILLION Market, page-21
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $41.29M | |||
| Open | High | Low | Value | Volume |
| 3.2¢ | 3.2¢ | 3.2¢ | $30.50K | 953.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1747120 | 3.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.3¢ | 850000 | 3 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| SNT (ASX) Chart |